Basiliximab induction therapy for live donor kidney transplantation: A long-term follow-up of prospective randomized controlled study

Clinical and Experimental Nephrology

Volumn 12, Issue 5, 2008, Pages 376-381

  Sheashaa, Hussein A ^a   Bakr, Mohamed A ^a   Ismail, Amani M ^a   Mahmoud, Khaled M ^a   Sobh, Mohamed A ^a   Ghoneim, Mohamed A ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Basiliximab; IL2 receptor antagonists; Renal transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; METHYLPREDNISOLONE; STEROID; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; STEROIDS; TREATMENT OUTCOME;

EID: 51849113850     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-008-0044-7     Document Type: Article

References (21)

1. H Sollinger B Kaplan M Pescovitz B Philosophe A Roza K Brayman K. Somberg 2001 Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection Transplantation. 72 1915 9
2. DC Brennan K Flavin JA Lowell TK Howard S Shenoy S Burgess S Dolan JM Kano M Mahon MA Schnitzler R Woodward W Irish GG. Singer 1999 A randomized, double-blinded comparison of thymogloublin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients Transplantation. 67 1011 1018
3. HA Bock H Gallati RM Zürcher M Bachofen MJ Mihatsch J Landmann G. Thiel 1995 A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation Transplantation. 59 830 40
4. A Yussin Z. Shapira 2000 Single-bolus high-dose ATG for prophylaxis of rejection in renal transplantation- a prospective, randomized study Transplant Int. 13 S293 4
5. ML. Henry 1997 Induction therapy Curr Opin Organ Transplant. 2 49 53
6. Danovitch GM. Immunosuppressive medications and protocols for kidney transplantation. In: GM Danovitch, editor. Handbook of Kidnet Transplantation, 4th edn. 2005. pp 72-134.
7. BD Maes YF. Vanrenterghem 1999 Anti-interleukin-2 receptor monoclonal antibodies in renal transplantation: Editorial comments Nephrol Dial Transplant. 14 2824 6
8. Olyaei AJ, Thi K, Le Mattas AM, Bennett WM. Use of basiliximab and daclizumab in kidney transplantation. Prog Transplant. 2001;1:33-9.
9. B Nashan S Light IR Hardie A Lin RJ. Johnson 1999 Reduction of acute renal allograft rejection by daclizumab Transplantation. 67 110 5
10. B Nashan R Moore P Amlot AG Schmidt K Abeywickrama JP. Soulillou 1997 Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients Lancet. 350 1193 8
11. BD Kahan PR Rajagopalan M Hall 1999 Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody Transplantation. 67 276 84
12. LL Mulloy F Wright ML Hall M. Moore 1999 Simulect (Basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors Transplant Proc 31 1210 3
13. HA Sheashaa MA Bakr AM Ismail MA Sobh MA. Ghoneim 2003 Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial J Nephrol 16 3 393 8
14. HA Sheashaa MA Bakr AM Ismail OE Gheith KF El-dahshan MA Sobh MA. Ghoneim 2005 Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study Am J Nephrol 25 3 221 5
15. I Buyse R Decorte H. Cuppens 1993 Rapid DNA typing of class II HLA antigens using the polymerase chain reaction and reverse dot blot hybridization Tissue Antigens. 48 1
16. L Racusen K Solez R Colvin S Bonsib 1999 The Banff 97 working classification of renal allograft pathology Kidney Int. 55 713 23
17. SV Onrust LR. Wiseman 1999 Basiliximab Drugs 57 2 207 13
18. C Ponticelli A Yussim V Cambi C Legendre G Rizzo 2001 Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine Transplant Proc 33 1009 10
19. G Offner M Broyer P Niaudet C Loirat M. Mentser 2002 A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients Transplantation. 74 961 6
20. R Grenda A Watson K Vondrak NJ Webb J Beattie 2006 A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation Am J Transplant 7 1666 72
21. AC Webster EG Playford G Higgins JR Chapman JC. Craig 2004 Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials Transplantation. 77 2 166 76